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Background: Intracranial pediatric germ cell tumors (GCTs) are rare and heterogeneous neoplasms and vary in
histological differentiation, prognosis and clinical behavior. Germinoma and mature teratoma are GCTs that have a
good prognosis, while other types of GCTs, termed nongerminomatous malignant germ cell tumors (NGMGCTs),
are tumors with an intermediate or poor prognosis. The second group of tumors requires more extensive drug and
irradiation treatment regimens. The mechanisms underlying the differences in incidence and prognosis of the
various GCT subgroups are unclear.
Results: We identified a distinct mRNA profile correlating with GCT histological differentiation and prognosis, and
also present in this study the first miRNA profile of pediatric primary intracranial GCTs. Most of the differentially
expressed miRNAs were downregulated in germinomas, but miR-142-5p and miR-146a were upregulated. Genes
responsible for self-renewal (such as POU5F1 (OCT4), NANOG and KLF4) and the immune response were abundant
in germinomas, while genes associated with neuron differentiation, Wnt/b-catenin pathway, invasiveness and
epithelial-mesenchymal transition (including SNAI2 (SLUG) and TWIST2) were abundant in NGMGCTs. Clear
transcriptome segregation based on patient survival was observed, with malignant NGMGCTs being closest to
embryonic stem cells. Chromosome copy number variations (CNVs) at cytobands 4q13.3-4q28.3 and 9p11.2-9q13
correlated with GCT malignancy and clinical risk. Six genes (BANK1, CXCL9, CXCL11, DDIT4L, ELOVL6 and HERC5)
within 4q13.3-4q28.3 were more abundant in germinomas.
Conclusions: Our results integrate molecular profiles with clinical observations and provide insights into the
underlying mechanisms causing GCT malignancy. The genes, pathways and microRNAs identified have the
potential to be novel therapeutic targets.
Background
The reported incidence of primary germ cell tumors
(GCTs) of central nervous system (CNS) in children is
significantly higher in Taiwan, Japan and Korea com-
pared to Western countries. The comparative incidences
are 15.3% in Japan, 14.0% in Taiwan, 11.2% in Korea,
2 . 3 %i nU S A ,a n d2 . 5 %i nG e r m a ni nv a r i o u sr e p o r t e d
series [1-5]. There is still no explanation for this
extreme geographic and ethnic difference between the
three Asian series and the two Western series (p <
0.0001) [5]. Genomic differences need to be considered
and evaluated.
Primary CNS GCT consists of several subtypes with
different degrees of histological differentiation and malig-
nancy. According to histological differentiation, related
tumor markers, and secreted protein markers, these
tumors can be classified into germinomas and nongermi-
nomatous GCTs (NGGCTs), the latter including embryo-
nal carcinoma (EC), yolk sac tumors (YST),
choriocarcinoma (CC), teratoma (mature teratoma,
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nant differentiation) and mixed GCTs [6]. For NGGCTs,
except for benign mature teratoma, all of the other
tumors present with diverse malignancies and therapeu-
tic sensitivities when compared to germinomas and are
grouped together as nongerminomatous malignant GCTs
(NGMGCTs). NGMGCTs require more extensive drug
and irradiation treatment regimens, have a higher recur-
rence rate and a lower survival rate [7,8]. Clinically, >50%
of pediatric CNS GCTs are germinomas, while the major-
ity of remaining tumors are NGMGCTs [5,9]. Histologi-
cally, germinoma is the most undifferentiated GCT and
is composed of undifferentiated large cells that resemble
primordial germinal elements. Among the NGGCTs, the
histological picture differs depending on the diagnosis.
EC contains undifferentiated stem cells resembling the
embryonic inner cell mass (ICM). YST and CC corre-
spond to the extra-embryonic differentiation along meso-
blast and trophoblast lines, respectively. This contrasts
with teratomas, which consist of differentiated derivatives
that include all three germ layers with or without incom-
pletely differentiated tissue elements, like neuroepithe-
lium, which resembles fetal tissue. CNS GCTs often
present with more than one histological component and
are then classified as mixed GCTs [7,10,11].
GCTs are presumed to arise from mutated primordial
germ cells (PGCs) of genital ridge origin or dysfunction
totipotent embryonic cells [12]. Investigation of the dif-
ferent genetic compositions in ECs and ES cells may
provide clues about the reduced dependency on external
cues for self-maintenance that exist among GCTs,
thereby benefiting tumorigenesis research on ECs as
well as applications for human ES cells (see also a
review article by Werbowetski-Ogilvie et al. [13]). Glo-
bal gene expression studies in human embryonic stem
cells and human pluripotent germ cell tumors have
shown that the gene expression patterns of human ES
cell lines are similar to those of the human embryonal
carcinoma cell samples but are more distantly related to
those of seminoma samples [12,14]. Genes that are
expressed at significantly greater levels in human ES and
embryonal carcinoma cell lines than in control samples
were pinpointed and are possible candidates for involve-
ment in the maintenance of a pluripotent undifferen-
tiated phenotype [12]. Wnt and Notch pathway genes
are overexpressed in the pluripotent human embryonal
carcinoma cell line NTERA2 and in embryonic stem
cells [15]. These include members of the frizzled gene
family (FZDI, FZD3, FZD4, FZD5, FZD6), which
encodes receptors for the Wnt proteins, the Frizzled
Related Protein family (SFRPI, SFRP2, FRZB, SFRP4),
which encode soluble Wnt antagonists and also ligands
and receptors of the Notch pathway (Dlkl, Jaggedl;
Notchl, Notch2, Notch3) [15].
The histological differences between the various differ-
ent GCTs are mirrored by their gene expression profiles
[16,17]. Genomic studies have been conducted on
GCTs, most notably on Caucasian adult gonadal ones
[12,16]. However, only limited gene profiling studies
have focused on primary pediatric CNS GCTs, and, to
our knowledge, no transcriptome profiling work on
Asian cases has been reported. A very recently paper
studied global mRNA expression patterns in pediatric
malignant GCTs arising from the testis, the ovary, the
sacrococcygeal region and the brain, and then compared
these with adult testicular tumors. These results showed
that there is no segregation of GCTs with the same his-
tology at different sites or at different ages, within the
pediatric range. However, clear segregation of pediatric
and adult tumors, most conspicuously among the YSTs,
was observed [17]. The pediatric seminomas are signifi-
cantly enriched for genes associated with a self-renewing
pluripotent phenotype, whereas the pediatric YSTs are
significantly enriched for genes associated with differen-
tiation and proliferation [17]. These results suggest that
the observed clinical differences between pediatric CNS
GCTs from different ethnic backgrounds or prognosis
groups may also be detected using genomic analysis.
MicroRNAs (miRNAs) are small RNAs of 18-24
nucleotides in length that are involved in the regulation
of gene expression and hence a variety of biological pro-
cesses through post-transcriptional RNA interference-
based mechanisms. Matured miRNAs interact and inhi-
bit target mRNAs and result in translational repression
or mRNA cleavage [18-20]. In medulloblastoma (MB),
an aggressive brain malignancy with a predominant inci-
dence in childhood, a high throughput miRNA profiling
analysis found that only a few miRNAs displayed upre-
gulated expression, while most of them, such as miR-9
and miR-125a, were downregulated in the tumor sam-
ples, suggesting a tumor growth-inhibitory function [21].
Moreover, the same group identified miRNAs downre-
gulated in human MBs with high Hedgehog (Hh) signal-
ing, which is one of the pathogenesis mechanisms of
MB [22]. Differential miRNAs, such as miR-184, have
been identified and found to correlate with prognosis,
differentiation, and apoptosis in pediatric neuroblastoma
[23]. A high-throughput miRNome analysis of adult
gonadal GCTs has been published, and in each GCT
subtype the miRNA patterns are quite different [24]. For
GCTs in children, only limited miRNA data has been
reported.
Genomic copy number variation (CNV) in GCTs of
adulthood has been extensively investigated. Gain of 12p
in up to 80% of cases of adult testicular GCTs [25,26].
In contrast, comparatively little genomic CNV investiga-
tion has been conducted on childhood GCTs. Using
metaphase comparative genomic hybridization (CGH), a
Wang et al. BMC Genomics 2010, 11:132
http://www.biomedcentral.com/1471-2164/11/132
Page 2 of 19wide range of CNVs has been described in pediatric
GCTs, including gains on 1q, 2p, 3, 7, 8, 13, 14, 20q, 21,
and X, as well as losses on 1p36, 4q, 6q, 11, 13 and 18;
but none are seen consistently [27-29]. This may due to
either the heterogeneity of the GCTs, or the different
algorithms that were applied to identify the CNV
regions. In 2007, Palmer et al.u s e d3 4G C T s( 2 2y o l k
sac tumors (YSTs), 11 germinomatous tumors and one
metastatic embryonal carcinoma), which had occurred
in children from birth to age 16, for CNV analysis. Most
of their cases were from the testis, the ovary and the
sacrococcygeal region and only two germinomas and
one YST brain BCT were included [30]. Gain of 12p
was found to be present in 53% of primary MGCTs of
children aged 5-16 and was also observed in four of
fourteen YSTs affecting children less than 5 years old.
The YSTs showed an increased frequency of 1p loss (p
= 0.003), 3p gain (p =0 . 0 2 ) ,4 ql o s s( p =0 . 0 7 )a n d6 q
loss (p = 0.004) compared to the germinomatous tumors
[30].
In this study, we applied genomic approaches to
explore the molecular messages governing the ethnic
and prognosis differences of CNS GCTs. Both mRNA
and miRNome expression patterns were studied in
pediatric primary CNS GCTs. To provide novel insights
into GCT pathogenesis, the transcriptomes of all GCT
cases were further compared to those of ES cell lines
from both Caucasian and Taiwanese genetic back-
grounds [12,23]. Copy number variations (CNVs) in dif-
ferent GCT subtypes were also measured to evaluate
their possible influence on gene expression traits.
Finally, the transcriptomes of our patients were orga-
nized into functional modules in order to identify the
dominant biological processes and key genes in the ger-
minomas and NGMGCTs; this sought to help explain
the clinical observations associated with these tumors.
Results
Clinical aspects of primary pediatric CNS GCTs examined
In our series of 176 cases of primary pediatric CNS
GCTs, 58.5% were germinoma and 41.5% were nonger-
minomatous GCTs (NGGCTs). Among the germinomas,
62.1% had a histological diagnosis, while the remaining
37.9% of cases had a presumptive diagnosis. For
NGMGCTs, 90.3% had a histological diagnosis, with the
remaining cases having a presumptive diagnosis. Each
presumptive diagnosis of the GCTs was made according
to the tumor’s clinical features, neuroimaging results,
serum tumor marker level (alpha fetal protein [AFP],
beta human chorionic gonadotropin level [beta-hCG])
and response to radiotherapy and/or chemotherapy.
Subtypes of NGGCTs included mature teratomas (5.1%),
various NGMGCTs including immature teratomas,
mixed GCTs, pure YSTs, and tumors diagnosed by
tumor markers (35.2%), and unclassified GCTs (1.7%)
(Additional file 1-A) The 5-year, 10-year and 15-year
overall survival rates for the germinomas and
NGMGCTs were 82.2%, 74.5% and 74.5% for the germi-
nomas and 66.1%, 45.4% and 30.3% for the NGMGCTs.
Kaplan-Meier estimator analysis and log-rank test
revealed that the germinoma patients had a better over-
all survival than the NGMGCT patients (p = 0.0005;
Figure 1A). Accordingly, therapeutic classification of the
GCTs represents prognostic factor-based classification
and management. However, the therapeutic classifica-
tion of CNS GCTs is quite different between the CNS
GCTs and extra-CNS GCTs, because of rareness of sys-
temic metastasis of the CNS GCTs [9]. According to the
clinical and therapeutic classification of CNS GCTs [9],
in our series of CNS GCTs in children, 113 cases
(63.6%), including 103 germinomas, 9 mature teratomas,
and 1 mixed germinoma and mature teratoma, were
categorized as members of the good prognostic group
(GPG), 40 cases, including 12 immature teratomas and
19 mixed GCTs, were categorized as members of the
intermediate prognostic group (IPG), and 14 cases,
including 10 pure yolk sac tumors and 4 mixed GCTs
dominated by yolk sac tumors, were categorized as
members of the poor prognostic group (PGG) [9]. For
the 21 cases that underwent genomic studies (Additional
file 1-B), cases 1-12 could be categorized as members of
the GPG and these included 9 pure germinomas, 2
mature teratomas, and 1 mixed germinoma- mature ter-
atoma. Cases 13-18 could be categorized as members of
the IPG and included 5 mixed GCTs and 1 immature
teratoma. Cases 19-21 belonged to the PPG and
included 3 mixed GCTs with YST component predomi-
nance (Additional file 1-B).
The MicroRNA signatures associated with the different
pediatric CNS GCT prognostic groups
Global miRNA expression patterns (the “miRNome”)
were analyzed in 12 cases (case 1-6, 12-14 & 16-18 in
Additional file 1-B). Differentially expressed miRNAs
that correlated with the germinoma group (GPG) and
the NGMGCT group (IPG/PPG) were identified by 2-
tailed Student’s t-test with a significance level of p <
0.05 plus ≧2-fold changes. Their discrimination ability
was assessed by principle component analysis (PCA).
Thus, patients within the different prognosis groups
were separated by their distinct miRNA profiles (Figure
1B). A heat map of these miRNAs indicates the unique
expression levels associated with each prognostic group
(Figure 1C). Two miRNAs (hsa-miR-142-5p and hsa-
miR-146a) are enriched in the germinoma group (GPG)
and 19 miRNAs are enriched in the NGMGCT group
(IPG/PPG) (Figure 1C). The differential expression levels
of the miRNAs across the two different histological
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Page 3 of 19Figure 1 MiRNome analysis of childhood CNS GCTs.( A) Overall survival rates of GCTs of different histological subtypes. In total, 161 patients
were followed up for up to 20 years. These were then subjected to Kaplan-Meier survival analysis. Numbers in parentheses are case numbers of
each tumor subtype. Vertical lines indicate the censored survival observations. (B) Principal component analysis (PCA) using the filtered miRNAs
(p < 0.05 and fold change ≧2). Each spot represents a single array. (C) A heat map shows the miRNAs enriched in the different prognostic
groups. MiRNAs in red showed increased expression, while those in blue showed decreased. (D-E) Validation of miRNA array results by real-time
PCR. The mean expression levels of the target miRNAs are compared to that of the U6 small nuclear RNA control. Results are expressed as the
mean ± standard deviation (SD) (E). The miRNAs’ array hybridization signals are also shown (D).
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GCTs were organized by array hybridization intensity
(Figure 1D) and verified by quantitative PCR (qPCR)
(Figure 1E). The expression levels of hsa-miR-142-5p,
hsa-miR-335 and miR-654-3p were found to be different
when the patients in these two different groups were
compared (Figure 1D-E).
Stem cell traits associated with the expression patterns of
protein-coding gene within the NGMGCT group
The expression patterns of the protein-coding genes of
the same 12 cases described above together with 1 addi-
tional germinoma case (case 7 in Additional file 1-B),
were also analyzed. In total, 399 probe sets were specifi-
cally enriched in the germinoma group (GPG) compared
to 292 ones in NGMGCT group (IPG/PPG) with a strict
positive false discovery rate (pFDR) threshold of q <
0.001 (Additional file 2). The discrimination ability of
these probe sets was assessed by a multidimensional
scaling (MDS) assay (Figure 2A). The top 50 transcripts
most strongly expressed in the germinoma group (GPG)
or the NGMGCT group (IPG/PPG) among the pediatric
CNS GCTs are shown in Table 1 and 2, respectively. In
the germinoma group (GPG), the presence of MMP-12,
which is involved in promoting tumor metastasis, needs
to be noted [31] (Table 1, labeled by a asterisk). Podo-
planin, a significant lymphatic endothelial cell marker, is
also found in the top 50 genes of this group. Podoplanin
is expressed by cancer associated fibroblasts (CAFs) and
has been shown to be correlated with a poor prognosis
in lung adenocarcinomas [32]. In addition, POU5F1
(alias OCT4), a significant transcription factor involved
in maintaining the stemness of ES cells [33], is also
among the top 50 genes in this group (Table 1, labeled
by asterisks). Among the members of the GP group, the
NANOG and KLF4 stemness factors are overexpressed
(q < 0.01, data not shown). These stemness genes can
induce pluripotency in somatic cells and then reprogram
them back to a pluripotent status so that they have the
essential characteristics of embryonic stem (ES) cells
[33,34]. Another pluripotency associated gene, DPP4
(developmental pluripotency associated 4), is also highly
expressed in germinomas. Finally, spermatogenesis- and
oogenesis-related genes, such as SPATA2 (spermatogen-
esis associated 2), SPESP1 (sperm equatorial segment
protein 1) and GTSF1 (gametocyte specific factor 1),
w e r ea l s of o u n dt ob ee x p r e s s e dm o r ea b u n d a n t l yi n
germinomas than in NGMGCTs (Table 1).
In the NGMGCT group (IPG/PGG), genes involved in
cell adhesion and migration, such as cadherin 11
(CDH11) and various collagens, are abundantly
expressed (Table 2, labeled by asterisks). SNAI2 (alias
SLUG) and TWIST2, two key regulators involved in
neural crest development and epithelial-mesenchymal
transition (EMT), are also highly expressed in this
group; these proteins are known to contribute heavily to
cell motility and tumor metastasis [35]. Finally, genes
such as FZD7 and SFRP1, which are involved in
the Wnt signaling pathway, are also highly expressed
(Table 2).
It has been recognized that aggressive and poor prog-
nostic glioblastomas, as well as other tumors, acquire
characters reminiscent of embryonic stem cells (ESCs)
and the degree of ESC gene expression correlates with
p a t i e n tp r o g n o s i s[ 3 6 ] .I ti sp o s s i b l et h a tp e d i a t r i cC N S
GCTs, especially the poor prognosis NGMCGTs, are
reminiscent of ES cells. We compared the gene expres-
sion patterns of pediatric GCTs to those of Caucasian
and Taiwanese ESC lines. PCA analysis showed that
NGMGCTs have a closer relationship to ES cells (Figure
2 B ) .T h eE S Ca r r a yd a t af r o mf i v ed i f f e r e n td a t as e t s
(GSE7234, GSE7896, GSE9440 (for the Taiwanese ESC
lines) and GSE9832 and GSE13828 (for the Caucasian
ESC lines) were all grouped together (Figure. 2B) and
possible batch effects during array analysis were ignored.
To provide quantitative insights, we calculated the rela-
tionships between the GCT subgroups and the ESCs by
measuring the average linkage Euclidean distances
between them. NGMGCTs were found to closer to the
ESC than the germinomas (Figure. 2C).
The closer relationship between NGMGCTs and ESCs
was verified further by hierarchical clustering. As shown
in Figure. 2D, clearly the NGMGCTs and ESCs form
one group while the germinomas form another. In total,
100 genes commonly show high-expression between
NGMGCTs and ESCs (Figure. 2D). Among these genes
the following are notable. IRS1 (Insulin receptor sub-
strate 1) is an effector of sonic hedgehog mitogenic sig-
naling in cerebellar neural precursors [37] and regulates
murine embryonic stem cell self-renewal [38] (Figure.
2D, underlined and in bold). MID1 is a RING finger
transcription factor involved in Opitz syndrome and is
expressed strongly in undifferentiated cells in the central
nervous system as well as the gastrointestinal and
respiratory tract epithelium of human embryos [39].
Embryonic oncogenes such as NET1 (neuroepithelial
cell transforming gene 1), HIF3A (hypoxia inducible fac-
tor 3, alpha subunit), ETS2, RUNX1T1, and the Wnt
signaling pathway genes (FZD7 and SFRP1) also appear
in this cluster (Figure. 2D). However, notably, two key
EMT genes, SNAI2 (SLUG) and TWIST2, are uniquely
expressed by NGMGCTs (Figure. 2D).
Among the genes commonly found to show abundant
expression in both the ESCs and germinomas, the pluri-
potent stemness genes DPP4 and POU5F1 (OCT4) are
significant (Figure. 2D, underlined and in bold). The
array hybridization signal for POU5F1 is shown in Fig-
ure. 2E. The high expression of POU5F1, as well as that
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Page 5 of 19Figure 2 Gene expression analysis of the different GCT subgroups.( A) A multidimensional scaling (MDS) plot containing the differentially
expressed genes (690 probe sets, q < 0.001). Each spot represents a single array. (B) A comparison of the transcriptome traits between ESCs and
NGMGCTs by principal component analysis (PCA). (C) Relationships between ESCs, germinomas and NGMGCTs. Average linkage Euclidean
distances between the tissues and ESC were calculated using genes distinguishing the filtrated 690-probe set. The confidence limits shown
represent the standard error. (D) A heat map shows genes enriched in the ESCs and in the different prognostic groups (q < 0.001). (E-F) Real-
time PCR validation of the microarray data. Mean expression levels of the examined genes were compared to that of the GAPDH control. Each
bar represents a different individual (F). The genes’ array hybridization signals are also shown (E).
Wang et al. BMC Genomics 2010, 11:132
http://www.biomedcentral.com/1471-2164/11/132
Page 6 of 19Table 1 Top 50 known genes in TW germinomas
Probe Set ID UniGene ID Gene Title Gene Symbol Location
207522_s_at Hs.513870 ATPase; Ca++ transporting; ubiquitous ATP2A3 chr17p13.3
1552487_a_at Hs.459153 basonuclin 1 BNC1 chr15q25.2
219928_s_at Hs.511983 calcium binding tyrosine-(Y)-phosphorylation regulated CABYR chr18q11.2
219578_s_at Hs.547988 cytoplasmic polyadenylation element binding protein 1 CPEB1 chr15q25.2
1564491_at Hs.590784 chromosome X open reading frame 18 CXorf18 chrXq27.2
206588_at Hs.131179 deleted in azoospermia-like DAZL chr3p24.3
228057_at Hs.480378 DNA-damage-inducible transcript 4-like *DDIT4L chr4q23
221630_s_at Hs.223581 DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 DDX4 chr5p15.2-p13.1
220004_at Hs.125507 DEAD (Asp-Glu-Ala-Asp) box polypeptide 43 DDX43 chr6q12-q13
220493_at Hs.98586 doublesex and mab-3 related transcription factor 1 DMRT1 chr9p24.3
232985_s_at Hs.317659 developmental pluripotency associated 4 *DPPA4 chr3q13.13
210868_s_at Hs.412939 ELOVL family member 6; elongation of long chain fatty acids *ELOVL6 chr4q25
1555299_s_at — endogenous retroviral family W; env(C7); member 1 (syncytin) ERVWE1 chr7q21-q22
1553614_a_at Hs.652066 hypothetical protein FLJ25694 FLJ25694 chr13q21.31
207899_at Hs.1454 gastric inhibitory polypeptide GIP chr17q21.3-q22
227711_at Hs.524476 gametocyte specific factor 1 *GTSF1 chr12q13.2
219863_at Hs.26663 hect domain and RLD 5 *HERC5 chr4q22.1
209398_at Hs.7644 histone cluster 1; H1c HIST1H1C chr6p21.3
214455_at Hs.553506 histone cluster 1; H2bc HIST1H2BC chr6p21.3
223861_at Hs.298312 HORMA domain containing 1 HORMAD1 chr1q21.2
217522_at Hs.660831 potassium channel; subfamily V; member 2 KCNV2 chr9p24.2
219955_at Hs.685462 LINE-1 type transposase domain containing 1 L1TD1 chr1p31.3
220665_at Hs.242183 leucine zipper protein 4 LUZP4 chrXq23
205668_at Hs.153563 lymphocyte antigen 75 LY75 chr2q24
229475_at Hs.651245 maelstrom homolog (Drosophila) MAEL chr1q24.1
207534_at Hs.73021 melanoma antigen family B; 1 MAGEB1 chrXp21.3
206218_at Hs.113824 melanoma antigen family B; 2 MAGEB2 chrXp21.3
214397_at Hs.25674 methyl-CpG binding domain protein 2 MBD2 chr18q21
204580_at Hs.1695 matrix metallopeptidase 12 (macrophage elastase) *MMP12 chr11q22.3
204702_s_at Hs.404741 nuclear factor (erythroid-derived 2)-like 3 NFE2L3 chr7p15-p14
229352_at Hs.657932 sperm equatorial segment protein 1 *SPESP1 chr15q23
209626_s_at Hs.520259 oxysterol binding protein-like 3 OSBPL3 chr7p15
204879_at Hs.468675 podoplanin *PDPN chr1p36.21
210265_x_at Hs.450254 POU class 5 homeobox 1 pseudogene 3 *POU5F1(OCT4) chr12p13.31
225579_at Hs.274415 PQ loop repeat containing 3 PQLC3 chr2p25.1
204086_at Hs.30743 preferentially expressed antigen in melanoma PRAME chr22q11.22
218700_s_at Hs.115325 RAB7; member RAS oncogene family-like 1 RAB7L1 chr1q32
1558668_s_at Hs.351068 spermatogenesis associated 22 *SPATA22 chr17p13.3
223883_s_at Hs.309767 serine/threonine kinase 31 STK31 chr7p15.3
1553599_a_at Hs.506504 synaptonemal complex protein 3 SYCP3 chr12q
39318_at Hs.2484 T-cell leukemia/lymphoma 1A TCL1A chr14q32.1
206413_s_at Hs.510368 T-cell leukemia/lymphoma 1B TCL1B chr14q32.1
215356_at Hs.646351 tudor domain containing 12 TDRD12 chr19q13.11
223530_at Hs.144439 tudor and KH domain containing TDRKH chr1q21
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verified by qPCR (Figure 2F). In contrast, SNAI2
(SLUG) is overexpressed in NGMGCTs (Figure 2E-F).
Relationships between abundant microRNAs and their
target mRNAs
The most differentiating miRNAs between the histologi-
cal subgroups were used to predict their mRNA targets.
This was performed by examining whether there were
any candidate miRNA target genes, the expression of
which became significantly higher in a given group of
tumors, which also showed a correlated reduction in the
related miRNAs. This analysis yielded miRNA-target
pairs that showed opposite expression patterns in the
same prognostic group (Table 3). In the germinoma
group, the expression levels of RUNX1T1 and THRB
were inversely correlated with expression of miR-146a,
and the levels of NRP1, SVIL and PDGFRA were inver-
sely correlated with the expression of miR-142-5p.
Furthermore, RUNX1T1 is a putative target of both
miR-142-5p and miR-146a (Table 3, underlined). In the
NGMGCT group, inverse correlation expressions were
also found between miRNAs and their candidate down-
stream targets (Table 3), specifically, miR-218, which is
an intragenic miRNA of the overexpressed SLIT2 gene
(Table 3, labeled by an asterisk).
The signature miRNAs in the same GCT prognosis
group were found to target the same mRNAs. miR-503
and miR-543 both target PAFAH1B1 and RNF138,
while miR-26a and miR-503 both target CREBL2 and
DNAJA2 (Table 3, underlined). In addition, FRAT2 is a
putative target of both miR-26a and miR-539, ATP11C
is a target of both miR-26a and miR-543, NMT1 is a
target of both miR-181c and miR-401, WNT2B is a tar-
get of both miR-218 and miR-503, N4BP1 is a target of
both miR-335 and miR-503, and OSBPL3 is a target of
both miR-410 and miR-543 (Table 3, underlined). Some
mRNAs are even targeted by more than two miRNAs:
NUP50 is targeted by three miRNAs (miR-26a, miR-218
and miR-503), while WAPAL is a target of four miRNAs
(miR-26a, miR-335, miR-433 and miR-539 (Table 3, in
bold and underlined, respectively). Thus it would seem
that there are complex and highly interactive miRNA-
mRNA genetic networks active in germinomas and
NGMGCTs.
Functional module and pathway analysis as a framework
for the interpretation of GCT biology
T h eg e n el i s to u t l i n e da b o v eg a v eu sp r e l i m i n a r y
insights into the functional consequences of detected
differential gene expression. To understand more about
how the gene expression profiles might be correlated
with pathogenesis and the various clinical phenotypes as
well as to provide quantitative evidence, the signature
mRNAs were subjected to a Gene Ontology (GO) data-
base search [40] in order to find statistically overrepre-
sented functional groups within the gene lists. The
WebGestalt web tool [41] was applied to provide statis-
tical analysis and visual presentation of the results. The
GO categories of biological processes that were statisti-
cally overrepresented (p < 0.05) among genes of the ger-
minoma group are shown in Figure 3A. Genes CHEK2
and HUS1, which are involved in the DNA damage
checkpoint, were significantly overexpressed in germino-
mas (p = 3.45*10e-2; Figure 3A, panel 1). Another sig-
nificant biological process associated with this group is
related to the immune system processes (p = 2.64*10e-2;
Figure 3A, panel 2, where the involved immune
response genes are shown). Other predominant pro-
cesses in the GP group include genes pertaining to
reproduction (p = 2.74*10e-2) and male gonad develop-
ment (p = 1.24*10e-2; Figure 3A, panel 3).
In contrast, the principal functions of the p-regulated
genes in the NGMGCT group (IPG/PPG) of pediatric
GCTs include those related to small GTPase (Rho pro-
tein especially) mediated signal transduction (Figure 3B,
panel 1), cell motility (Figure 3B, panel 2) and various
genes associated with active differentiation processes, in
particular neuron differentiation (Figure 3B, panel 3).
Seven genes involved in the Wnt receptor signaling
pathway are also significantly active in this group (p =
1.07*10e-4; Figure 3B, panel 1). When the genes (q <
0.001) are subjected to a KEGG pathway database to
obtain a similar module analysis using the DAVID 2008
web-based tool, the top-ranked canonical pathways in
the NGMGCT group again include cell motility (such as
Focal adhesion, ECM-receptor interaction and Gap
junction), axon guidance and Wnt signaling (Figure 3C).
Expression of Wnt pathway genes (such as FZDI, FZD3,
FZD4, FZD5, FZD6 and SFRP1, SFRP2, FRZB, SFRP4)
have been previously reported in a pluripotent human
Table 1: Top 50 known genes in TW germinomas (Continued)
227642_at Hs.156471 Transcription factor CP2-like 1 TFCP2L1 chr2q14
228505_s_at Hs.487510 transmembrane protein 170 TMEM170 chr16q23.1
208275_x_at Hs.458406 undifferentiated embryonic cell transcription factor 1 UTF1 chr10q26
1553197_at Hs.371738 WD repeat domain 21C WDR21C chr8q21.3
230193_at Hs.709837 WD repeat domain 66 WDR66 chr12q24.31
243161_x_at Hs.335787 zinc finger protein 42 homolog (mouse) ZFP42 chr4q35.2
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Page 8 of 19Table 2 Top 50 known genes in TW NGMGCTs
Probe Set ID UniGene ID Gene Title Gene Symbol Location
219935_at Hs.58324 ADAM metallopeptidase with thrombospondin type 1 motif; 5 ADAMTS5 chr21q21.3
219087_at Hs.435655 asporin ASPN chr9q22
205433_at Hs.420483 butyrylcholinesterase BCHE chr3q26.1-q26.2
236179_at Hs.116471 cadherin 11; type 2; OB-cadherin (osteoblast) *CDH11 chr16q22.1
212865_s_at Hs.409662 collagen; type XIV; alpha 1 *COL14A1 chr8q23
202311_s_at Hs.709197 collagen; type I; alpha 1 *COL1A1 chr17q21.33
229218_at Hs.489142 collagen; type I; alpha 2 *COL1A2 chr7q22.1
208096_s_at Hs.47629 collagen; type XXI; alpha 1 *COL21A1 chr6p12.3-p11.2
232458_at Hs.443625 Collagen; type III; alpha 1 (Ehlers-Danlos syndrome type IV) *COL3A1 chr2q31
212489_at Hs.210283 collagen; type V; alpha 1 *COL5A1 chr9q34.2-q34.3
221729_at Hs.445827 collagen; type V; alpha 2 *COL5A2 chr2q14-q32
202575_at Hs.405662 cellular retinoic acid binding protein 2 CRABP2 chr1q21.3
204619_s_at Hs.695930 chondroitin sulfate proteoglycan 2 (versican) CSPG2 chr5q14.3
232090_at Hs.584880 Dynamin 3 DNM3 chr1q24.3
204463_s_at Hs.183713 endothelin receptor type A EDNRA chr4q31.23
204400_at Hs.24587 embryonal Fyn-associated substrate *EFS chr14q11.2-q12
203184_at Hs.519294 fibrillin 2 (congenital contractural arachnodactyly) FBN2 chr5q23-q31
231130_at Hs.645700 FK506 binding protein 7 FKBP7 chr2q31.2
204359_at Hs.533710 fibronectin leucine rich transmembrane protein 2 FLRT2 chr14q24-q32
222853_at Hs.41296 fibronectin leucine rich transmembrane protein 3 FLRT3 chr20p11
243278_at Hs.656280 forkhead box P2 FOXP2 chr7q31
203706_s_at Hs.173859 frizzled homolog 7 (Drosophila) *FZD7 chr2q33
205498_at Hs.125180 growth hormone receptor GHR chr5p13-p12
227070_at Hs.631650 glycosyltransferase 8 domain containing 2 GLT8D2 chr12q
204237_at Hs.470887 GULP; engulfment adaptor PTB domain containing 1 GULP1 chr2q32.3-q33
224997_x_at Hs.533566 H19; imprinted maternally expressed transcript H19 chr11p15.5
215446_s_at Hs.102267 lysyl oxidase LOX chr5q23.2
204069_at Hs.526754 Meis homeobox 1 MEIS1 chr2p14-p13
207480_s_at Hs.510989 Meis homeobox 2 MEIS2 chr15q14
206201_s_at Hs.170355 mesenchyme homeobox 2 MEOX2 chr7p22.1-p21.3
203637_s_at Hs.27695 midline 1 (Opitz/BBB syndrome) MID1 chrXp22
222722_at Hs.708130 osteoglycin OGN chr9q22
213568_at Hs.253247 odd-skipped related 2 (Drosophila) OSR2 chr8q22.2
225975_at Hs.591691 protocadherin 18 PCDH18 chr4q31
203131_at Hs.74615 platelet-derived growth factor receptor; alpha polypeptide PDGFRA chr4q11-q13
212915_at Hs.434900 PDZ domain containing RING finger 3 PDZRN3 chr3p13
227419_x_at Hs.204947 placenta-specific 9 PLAC9 chr10q22.3
210809_s_at Hs.136348 periostin; osteoblast specific factor POSTN chr13q13.3
238852_at Hs.657841 Paired related homeobox 1 PRRX1 chr1q24
208131_s_at Hs.302085 prostaglandin I2 (prostacyclin) synthase PTGIS chr20q13.13
214043_at Hs.446083 protein tyrosine phosphatase; receptor type; D PTPRD chr9p23-p24.3
225946_at Hs.696433 Ras association (RalGDS/AF-6) domain family member 8 RASSF8 chr12p12.3
232060_at Hs.654491 receptor tyrosine kinase-like orphan receptor 1 ROR1 chr1p32-p31
205529_s_at Hs.368431 runt-related transcription factor 1; translocated to; 1 RUNX1T1 chr8q22
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Page 9 of 19embryonal carcinoma cell line and in an embryonic
stem cell [15], which supports the reliability of our func-
tional module analysis. FZDI, FZD4, FZD7 and SFRP1
are also in our gene list (Table 2 and Additional file 2).
The detailed locations of the signature genes are indi-
cated in Additional file 3 and Additional file 4.
Chromosome locations of the differentially expressed
genes and cytogenetic analysis of the GCTs
Gene set enrichment analysis (GSEA) was performed by
DAVID for all chromosomal arms using the entire gene
list. NGMGCTs were found to shows significantly tran-
script expression in the 7q21 cytoband region, which
contains 3 NGMGCT genes: GNG11 (guanine nucleo-
tide binding protein (G protein), gamma 11), GNAI1 (G
protein alpha inhibiting activity polypeptide 1) and
FZD1 (frizzled homolog 1). In germinomas, genes were
overexpressed at Xq27.1, 14q32.1 (TCL1A & 1B),
1p36.11 (CCDC21, ZNF593, FAM46B and C1orf135),
12q13.13, 6p21.33 (ABCF1, HIST1H2BK and C6orf136)
and 20q13.1-q13.2 (Figure 3D). The POU5F1 (OCT4)
germinoma gene, as well as SLC4A8, LOC57228 and
C12orf44, are overexpressed at chr12q13.13. The sper-
matogenesis associated gene SPATA2, as well as
PTPN1, are overexpressed at 20q13.1-q13.2 (Figure 3D).
It is likely that gene expression changes are attributable
to underlying chromosomal aberrations. To identify such
a correlation, we examined the cytogenetic abnormalities
present in each GCT prognosis subtype. Copy number
variation (CNV) analysis was performed on 15 pediatric
CNS GCT cases (7 pure germinomas, 3 pure mature ter-
atomas and 5 NGMGCTs; Additional file 1-B) in order
to detect chromosomal aberrations. A data set containing
125 Human 1 M HapMap samples (generated by the Par-
tek Inc.) was used as a copy number baseline. The aber-
rant chromosome regions in each tested individual are
summarized in Additional file 5. As shown in Figure. 4, 3
out of 5 NGMGCT cases have a reduced DNA copy
number between 4q13.3-4q28.3 (S1) and 9p11.2-9q13
(S2). The protein-coding genes and miRNAs located in
these changed regions are shown in Table 4. BANK1,
CXCL9, CXCL11, DDIT4L, ELOVL6 and HERC5 are
Table 2: Top 50 known genes in TW NGMGCTs (Continued)
202037_s_at Hs.213424 secreted frizzled-related protein 1 *SFRP1 chr8p12-p11.1
213139_at Hs.360174 snail homolog 2 (Drosophila) *SNAI2 (SLUG) chr8q11
228821_at Hs.709275 ST6 beta-galactosamide alpha-2;6-sialyltranferase 2 ST6GAL2 chr2q11.2-q12.1
209651_at Hs.513530 transforming growth factor beta 1 induced transcript 1 TGFB1I1 chr16p11.2
203083_at Hs.371147 thrombospondin 2 THBS2 chr6q27
229404_at Hs.708196 twist homolog 2 (Drosophila) *TWIST2 chr2q37.3
Table 3 Signature miRNAs and their predicted targets in the opposite prognostic group
miRNA Mapping Intragenic Predicted Targets p value
142-5p 17q22 ADAMTS5, BCHE, DCHS1, FIGN, FLJ10357, FLRT2, FZD7, HDAC4, MEIS2, NRP1, PDGFRA, PTPRD,
RUNX1T1, SGCD, SVIL
2.09E-10
146a 5q33.3 C5orf23, PTGFRN, RPESP, RUNX1T1, SRR, THRB 5.89E-07
let-7e 19q13.43 (NA) (NA)
26a 3p22.2 CTDSPL ATP11C, C7orf42, CREBL2, DNAJA2, FRAT2, NFE2L3, NUP50, TFAP2C, WAPAL, ZNF655 4.23E-07
133b 6p12.2 (NA) (NA)
181c 19p13.12 C17orf63, EPB41, NMT1 1.18E-03
154 14q32.2 (NA) (NA)
218 4p15.31 *SLIT2 NUP50, SFMBT1, WDR66, WNT2B, ZDHHC23, ZNF313 1.82E-02
335 7q32.2 N4BP1, PHTF2, SLC45A3, WAPAL 3.34E-04
376a 14q32.31 BNC1, MAN1C1 1.45E-02
410 14q32.31 AGPAT7, DLG3, NMT1, OSBPL3, RGS16, ROD1, ZNRF2 2.27E-04
433 14q32.2 RTL1 PCCB, WAPAL 4.50E-02
503 Xq26.3 CREBL2, DNAJA2, KIAA1333, MBP, N4BP1, NUP50, PAFAH1B1, RNF138, WNT2B 1.41E-07
539 14q32.2 CCDC88A, FRAT2, LBA1, MYCL1, PSME3, SNAP29, WAPAL, XPO6 4.75E-05
543 14q32.31 ARFGEF2, ATP11C, CSNK1D, CTF8, OSBPL3, PAFAH1B1, PPTC7, RNF138, SDF2L1 2.38E-05
NA: No miRNA target could be found in the opposite group.
Underlined: Genes targeted by 2 microRNAs.
In bold and underlined: Genes targeted by more then 2 microRNAs.
Wang et al. BMC Genomics 2010, 11:132
http://www.biomedcentral.com/1471-2164/11/132
Page 10 of 19Figure 3 Altered functional modules in the different pediatric GCT prognostic groups.( A-B) Gene set enrichment analysis according to
the Gene Ontology (GO) classification. Probe sets differentiating good prognostic CNS GCTs from intermediate/poor prognostic CNS GCTs were
subjected to the GO database search via the DAVID 2008 interface. The number of genes, gene symbols, their percentages and the p values for
each category that show significance (p < 0.05) and are enriched in either the good (A) or the intermediate/poor (B) prognostic group are listed.
(C) KEGG pathways significantly enriched in the TW NGMGCT genes. The number of genes, their percentages in terms of total genes, and the p
values for pathways that are significantly over-represented (p < 0.05 by the DAVID 2008 tool) are listed. (D) Distribution of signature genes on
the chromosome cytobands.
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Page 11 of 19within 4q13.3-4q28.3 and are relatively more abundant in
germinomas (Table 4 and Additional file 2). DDIT4L,
E L O V L 6a n dH E R C 5a r ea l s oa m o n gt h et o p5 0m o s t
dominant genes in germinomas (Table 1).
Discussion and Conclusions
GCT is a specific type of CNS tumor with several sub-
types. The two major forms of these tumors, germinoma
(GPG) and NGMGCT (IPG/PPG), present with different
clinical behaviors, differences in sensitivity to therapeu-
tic regimens and different outcomes. The overall survi-
val of patients with germinomas is significantly better
than that of patients with NGMGCTs in our series (Fig-
ure 1A) and this is similar to other previously reported
series [42,43]. To explore the molecular difference
between these two different histological/therapeutic
prognostic groups, we have identified with confidence a
number of differentially expressed miRNAs and mRNA;
these permit an interpretation of the clinical survival
variations and downstream hypothesis testing. The var-
ious divergent biological functions that correlate with
the clinical observations are also revealed.
Among these miRNAs, miR-142-5p and miR-146a are
upregulated in the pediatric germinomas (GP group)
when compared to the NGMGCTs (IPG/PPG). Up to
the present, no miRNA profile of pediatric GCTs has
been published. A miRNome report on adult gonadal
GCTs showed that, for each GCT subtype, the miRNA
patterns are quite different [24]. In their dataset, miR-
142-5p and miR-146a are also more abundant in adult
seminomas than in gonadal ECs [24]. In addition, let-7e,
miR-133b, miR-218 and miR-654-3p are also abundant
in both pediatric NGMGCTs and adult ECs (Figure 1C)
[24]. However, the notable discrepancies are miR-181c
and miR-218, the expression levels of which are more
abundant in adult testicular seminomas but are lower in
pediatric intracranial germinomas (Figure 1) [24]. The
unique expression pattern of these miRNAs in pediatric
CNS GCTs may reflect the differences in pathogenesis
mechanisms between adult and pediatric GCTs [17], or,
alternatively, the variation in genetic makeup between
Western and Taiwanese patients.
We also correlated the transcript levels of miRNAs to
their candidate targets in order to identify microRNA-
mRNA target pairs (Table 3). It has been shown that
some miRNAs, such as miR-1, can downregulate the
transcript levels of a large number of target genes in
mammalian cells [18]. Two large scale proteomic studies
published very recently have shown that, although some
microRNA target proteins are repressed without
Figure 4 Chromosomal aberrations in the TW germinomas, mature teratomas (MTs) and NGMGCTs. The red bars on the right side of the
chromosome idiograms indicate gain in these chromosomal regions, while blue bars indicate chromosomal loss. Two common copy number
variation (CNV) regions (S1 & S2) in 3 out of 5 NGMGCT cases are highlighted.
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Page 12 of 19detectable changes in mRNA levels, more than a third of
translational repressed targets also display detectable
mRNA destabilization and, for the more highly
repressed targets, mRNA destabilization usually makes
up the major component of repression [19,20]. Gene
expression microarrays can therefore be, and have been,
applied for the identification of downstream targets for
miRNAs [44-46]. However, proof of direct binding
between those miRNAs and target mRNAs, as well as
the direct translational repression of target mRNAs, is
still needed. Such confirmation will require more wetlab
experiments such as immunoblotting and reporter
assays.
When compared with NGMGCTs, the germinomas lar-
gely recapitulate the features of self-renewing pluripotent
human embryonic stem (hES) cells, such as involvement
of POU5F1 (OCT4), NANOG and KLF4 (q <0 . 0 1 ) .B o t h
seminomas and embryonal carcinomas are known to
express stem cell markers, such as POU5F1 and NANOG
[47,48]. In addition, in an attempt to find coordinated
overexpressed gene clusters in GCTs, Korkola et al. found
NANOG at chromosome 12p13.31 is overexpressed in
undifferentiated (embryonal carcinomas and seminomas)
tumors versus differentiated (teratoma, yolk sac tumor,
and choriocarcinoma) tumors [16]. By overexpressing
POU5F1, NANOG and KLF4, it is now possible to repro-
gram the transcriptomes of somatic primary cells, which
results in their dedifferentiation from matured cells to ES
cell-like iPS (induced pluripotent stem) cells [49]. The
abundant expression of these dedifferentiation factors in
germinomas therefore mirrors the more undifferentiated
histopathological characteristics of these tumors. Whereas






S1 4q13.3-4q28.3 75084501 131387610 ABCG2, ADAD1, ADH1A, ADH1B, ADH1C, ADH4, ADH5ADH6,
ADH7, AFF1, AGPAT9, AGXT2L1, AIMP1, ALPK1, ANK2, ANKRD50,
ANKRD56, ANTXR2, ANXA3, ANXA5, AP1AR, ARD1B, AREG,
ARHGAP24, ARSJ, ART3, ATOH1, BANK1, BBS7, BBS12, BDH2,
BMP2K, BMP3, BMPR1B, BTC, C4orf3, C4orf11, C4orf12, C4ord17,
C4orf21, C4ord22, C4orf26, C4orf29, C4orf31, C4ord32, C4orf33,
C4orf36, C4orf37, CAMK2D, CAPSP6, CCDC109B, CCDC158, CCNA2,
CCNG2, CCN1, CDKL2, CDS1, CENPE, CEP170L, CFI, CISD2,
CNOT6L, COL25A1, COPS4, COQ2, CXCL2, CXCL3, CXCL9, CXCL10,
CXCL11, CXCL13, CXXC4, CTP2U1, DAPP1, DDIT4L, DKK2, DMP1,
DNAJB14, DSPP, EEF1AL7, EGF, EIF4E, ELOVL6, EMCN, ENOPH1,
ENPEP, EPGN, EREG, EXOSC9, FABP2, FAM13A, FAM13AOS,
FAM47E, FAM175A, FAM190A, FAT4, FGF2, FGF5, FLJ20184, FRAS1,
G3BP2, GAR1, GDEP, GK2, GPRIN3, GRID2, GSTCD, H2AAFZ, HADH,
HELQ, HERC3, HERC5, HERC6, HNRPDL, HPGDS, HPSE, HSD17B11,
HSD17B13, HSPA4L, IBSP, IL2, IL21, INTS12, INTU, KIAA1109, KLHL8,
LARP1B, LARP7, LEF1, LIN54, LOC100192379, LOC256880,
LOC285419, LOC285456, LOC641518, LOC729338, LRIT3, MAD2L1,
MANBA, MAPK10, MAPKSP1, MEPE, METAP1, METTL14, MFSD8,
MMRN1, MRPL1, MRPS18C, MTHFD2L, MTTP, MYOZ2, NAAA,
NAP1L5, NDST3, NDST4, NEUROG2, NFKB1, NHEDC1, NHEDC2,
NKX6-1, NPNT, NUDT6, NUDT9, NUP54, OSTC, PAPSS1, PAQP3,
PARM1, PCNAP1, PDE5A, PDHA2, PDLIM5, PGRMC2, PHF17, PIGY,
PITX2, PKD2, PLA2G12A, PLAC8, PLK4, PPA2, PPBPL2, PPEF2,
PPM1K, PPP3CA, PRDM5, PRDM8, PRKG2, PRSS12, PTPN13, QRFPR,
RAP1GDS1, RASGEF1B, RCHY1, RG9MTD2, RPL34, RRH, SCARB2,
SCD5, SCLT1, SDAD1, SEC24B, SEC24D, SEC31A, SEP11, SGMS2,
SHROOM3, SLC10A6, SLC25A31, SLC39A8, SMARCAD1, SNCA,
SNHG8, SNORA24, SPARCL1, SPATA5, SPP1, SPRY1, *SYNPO2,
TACR3, TBCK, TET2, THAP6, THAP9, TIFA, TIGD2, TMEM150C,
TMEM155, TMSL3, TNIP3, TRAM1L1, TRPC3, TSPAN5, UBE2D3,





S2 9p11.2-9q13 44703105 70128535 ANKRE20A2, ANKRD20A3, ANKRD20A4, AQP7P1, AQP7P2, CBWD3,
CBWD5, CBWD6, CCDC29, FAM27A, FAM27B, FAM27C, FAM74A4,
FAM75A5, FAM75A7, FXOD4L2, FOXD4L3, FOXD4L4, FOXD4L5,
FOXD4L6, KGFLP1, LOC100133920, LOC440839, LOC440896,
LOC442421, MGC21881, PGM5P2
(No know ones)
Underlined and in bold: Genes which are relatively more dominant in germinomas.
Asterisk: Discussed in the text.
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Page 13 of 19such similarities have previously been described for adult
and pediatric seminomas [16,17,47,48], we now know that
this also applies to Asian pediatric CNS germinomas.
Although germinomas abundantly express the above
three stemness factors, it is NGMGCTs (IPG/PPG) who
show a closer gene expression pattern to ESCs (Figure
2C). This observation is consistent with pervious global
gene expression reports whereby the gene expression
patterns of human ES cell lines are similar to those of
the human embryonal carcinoma cell samples but are
more distantly related to those of seminoma samples
[12]. The close relationship between NGMGCTs and ES
cells supports the hypothesis that germinomas are clo-
sely related to primordial germ cells (PGCs), and EC
cells/NGMGCTs represent a reversion to a more ICM-
or primitive ectoderm-like cell type [12]. Whether ger-
minomas and zygotes/blastomeres share similar mRNA
or microRNA profiles is under investigation at present.
The close relationship between NGMGCTs and ES cells
may additionally be reflected in the worse prognosis for
these tumors. Recently, via novel genomic approaches, it
has been shown that aggressive and poor prognostic
tumors, such as glioblastomas, inherit preferential ES
cell gene expression profiles [36]. The similarity between
pediatric NGMGCTs and human ES cells may therefore
reflect the clinical observation that CNS NGMGCTs are
more malignant and show a higher fatality rate than
germinomas.
The close relationship in genetic makeup between
NGMGCTs and ESCs also suggest that factors other
than POU5F1 (OCT4), NANOG or KLF4 are responsi-
b l ef o rE S Cg e n ee x p r e s s i o n .I nt h i ss t u d y ,w ef o u n d
that two key epithelial-mesenchymal transition (EMT)
regulators, SNAI2 (SLUG) and TWIST2, are abun-
dantly expressed in the NGMGCT group (IPG/PPG)
(Table 2 and Figure 2D). It has been reported that
EMT transcription factors, SNAI1 (alias SNAIL) and
TWIST, can independently dedifferentiate mammalian
cancer cells and induces the generation of cancer
stem-like cells, which then form mammospheres [50].
It is possible that SNAI2 (SLUG) and TWIST2 behaves
like Snail and TWIST and can introduce malignancy
and stemness in pediatric GCTs. Targeting oncogenic
stemness genes or EMT-related embryonic signaling
pathways (such as the Wnt pathway, Figures 2D &3C)
m a yd i f f e r e n t i a t eah i g h l ym a l i g n a n tN G M G C Ti n t oa
more matured transcriptome type, thereby increasing
the sensitivity of these tumors to the classical thera-
peutic regimen of radical resection, irradiation and
chemotherapy, which would produce a better prog-
nosis for the patients.
In addition to stemness genes (such as genes involved
in reproduction and male gonad development), the ger-
minomas were found to overexpress genes involved in
the DNA damage checkpoint, which indicates active
DNA integrity checking in the germinomas and thereby
reflects why the clinical phenotype of germinomas has a
better prognosis (Figure 3A). Among the other genes
that were found to be expressed abundantly in germino-
matous tissues were genes associated with the immune
system process and this correlates with the abundant
lymphocytic infiltration of germinomas found during
histological observation. Relative to germinomas, we
observed a significant enrichment of overexpression of
differentiation and morphogenesis (especially neurogen-
esis) genes in NGMGCTs, which correlates with the dif-
ferentiated state of these tumor cells (Figure 3B). There
is also evidence of overexpression of genes in the Wnt/
b-catenin pathway in our dataset (Figures 3B-C), which
is consistent with previous studies of nonseminomatous
malignant GCTs [15,51]. In concordance with the higher
recurrence and disseminating clinical behaviors of
NGMGCTs, a significant enrichment for overexpression
of motility, tight junction, focal adhesion, and adherent
junction genes in NGMGCTs was observed (Figures 3B-
C). Our results thereby integrate molecular profiles with
clinical observations and provide a better understanding
of the underlying molecular mechanisms. The combined
targeting of hub genes involved in all these biological
modules by a cocktail therapy-like regimen may even-
tually lead to an alleviation of these malignant CNS
tumors.
During the submission of this manuscript, a very
recent reference based on testis GCTs identified gene
expression signatures that predicted outcomes in
patients with extra-cranial adult GCTs [52]. We com-
pared the age and tumor characteristics between our
series against the genomic study group of CNS GCTs in
children and the reported study of extra CNS GCTs in
adult men (Additional file 1-C) [52]. In our series and
the genomic study of CNS GCTs, both germinomas and
NGGCTs in children younger than 18 years old were
included, whereas Korkola’s study involved adult men
with nonseminomatous GCTs (NSGCTs) [52]. In our
series, 118 tumors were pure germinomas or tumors
with a germinoma component, 49 tumors were pure ter-
atoma or tumors with a teratoma component, and 27
cases were classified as YSTs including 10 pure YSTs,
11 tumors with a YST component, and 6 cases with
serum AFP elevation (pure immature teratomas
excluded). Among the 21 cases with genomic studies, 9
tumors were pure germinomas, 2 tumors were pure
mature teratomas, and 9 tumors were mixed GCTs,
including one mature teratoma with serum AFP eleva-
tion and one germinoma with serum AFP elevation. The
correlation of tumor characteristics between the studies
of Korkola et al. and ours in Additional file 1-C consti-
tuted the basis for the comparison of genomic molecular
Wang et al. BMC Genomics 2010, 11:132
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groups and histology between these two studies.
Korkola et al. concluded that using a 140-gene signa-
ture, they could predict 5-year overall survival (OS) (p <
0.001) [52]. Both our study and that of Korkola et al.
identified good outcome GCTs express gene sets
involved in immune function and the repression of dif-
ferentiation (such as POU5F1/OCT4), while poor out-
come GCTs express genes involved in active
differentiation (in particular, neuron differentiation) (Fig.
3) [52]. A 10-gene prognosis model was also built using
a univariate Cox model. When the samples were dichot-
omized by median score, there was significant separation
of the survival curves (p < 0.002) [52]. These 10 genes
w e r eS T X 6 ,C F L A R ,F N B P 1 ,I T S N 2 ,S Y N E 1 ,M A P 3 K 5 ,
PTGDS, PXMP2, IRAK4, and RABGAP1L [52]. Among
these 10 genes STX6 (syntaxin 6) and CFLAR (CASP8
and FADD-like apoptosis regulator) are over-expressed
in our germinoma group (q < 0.01). It will be interesting
to fit their prognosis signatures onto our dataset to see
whether GCTs of different anatomic locations, ages and
ethnic populations express similar prognosis genes.
However, since all the tissues used in our study were
freshly collected over the last 2 years, only one death
has been recorded so far (Additional file 1). As a result,
this work needs to be carried out at a later stage.
The variation in chromosome copy number variation
(CNV) regions between germinomas and NGMGCTs
were mapped to cytobands 4q13.3-4q28.3 and 9p11.2-
9q13 (Figure 4). Chromosome abnormality analysis of
adult testicular germ cell tumors (tGCTs) revealed that
all GCTs show 12p gain [25,26]. In 2007, Palmer et al.
used metaphase-based comparative genomic hybridiza-
tion (CGH) to analyze genomic imbalance in 34 pedia-
tric GCTs (22 yolk sac tumors (YSTs), 11
germinomatous tumors and one metastatic embryonal
carcinoma). The YSTs showed an increased frequency
of 1p loss (p = 0.003), 3p gain (p = 0.02), 4q loss (p =
0.07) and 6q loss (p = 0.004) compared to germinomas
[30]. Most of their cases were from the testis, the ovary
or the sacrococcygeal region and only 2 germinomas
and 1 YST brain GCTs were included [30]; this is a pos-
sible explanation of the discrepancies between their
r e s u l t sa n do u r s .W ea l s oo b s e r v e d4 ql o s si nt h e
NGMGCTs (including YSTs), suggesting that genomic
imbalance in this region, and the genes/miRNAs
encoded by this chromosomal region, may play a crucial
tumor suppressing role during NGMGCT pathogenesis
and affect clinical performance (Table 4). Six genes
(BANK1, CXCL9, CXCL11, DDIT4L, ELOVL6 and
HERC5) within 4q13.3-4q28.3 showed higher expression
levels in the germinomas (Table 4). DDIT4L, ELOVL6
and HERC5 are among the top 50 highly expressed
genes in germinomas (Table 1). A putative GCT tumor
suppressor gene SYNPO2 (Synaptopodin 2), also known
as myopodin, is also within the 4q13.3-4q28.3 deletion
region (Table 4). SYNPO2 has recently been shown to
have the highest predictive value when assessing 5-year
overall survival [52], which is consistent with a possible
role as a tumor suppressor. However, we do not observe
differential SYNPO2 expression between NGMGCTs
and germinomas (Table 4). It is unclear whether
SYNPO2 expression is also downregulated in Taiwanese
germinomas compared to normal brains. In addition,
whether survival predictors derived from Western cases
can be applied to Asian patients still awaits elucidation.
Recently two independent genome-wide association
studies (GWAS) have reported on susceptibility loci
associated with tGCT: Kanetsky et al. mapped seven
markers at 12p22 near KITLG (c-KIT ligand) and two
markers at 5q31.3 near SPRY4 (sprouty 4) [53]; further-
more Rapley et al. identified loci on chromosome 5, 6
and 12 [54]. A third locus, in an intron of BAK1, a gene
that promotes apoptosis, was also identified by Rapley et
al. [54]. Similarly, the CGH profiles in childhood GCTs
have been reported to resemble those in adults [55,56].
In terms of cytogenetics differences between the differ-
ent histological entities, loss of chromosome 19 and 22
material and gain of 5q14-q23, 6q21-q24 and 13q mate-
rial were found to occur at a significantly lower fre-
quency in seminoma adult tGCTs compared to non-
seminoma adult tGCTs [25]. Among Taiwanese pedia-
tric GCTs, no common copy number variation (CNV)
could be found in either the germinomas or the mature
teratomas (Figure 4). The divergence between our
results and published Caucasian ones may be partly due
to the different ethnic samples used, the application of
different bioinformatics algorithms and the fact that we
compared the differences between germinomas and
NGMGCTs but not common aberrations across all
GCTs.
In summary we have identified miRNome, mRNA sig-
natures and CNV regions that are associated with two
pediatric GCT histological entities (germinoma and
NGMGCTs) and two prognostic groups (GPG and IPG/
PPG). The clinical discrepancies between the two histo-
logical entities (germinomas of GPG and NGMGCTs of
IPG/PPG) are therefore mirrored by their differences in
global transcriptome patterns and their unique stem cell
traits. One of the interesting questions that remain is
whether pediatric GCTs from other ethnic background
also express similar transcriptome traits and CNV
regions. If Caucasian and Taiwanese GCTs possess
unique transcriptome traits, therapeutic and diagnostic
experience from Western countries may not be applic-
able directly to Asian or Taiwanese patients. Therefore,
the genes and miRNAs identified here hold the potential
of being novel therapeutic targets and may be used for
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example, is activated in NGMGCTs (Figure 3C), and
drugs targeting this specific pathway may hold potential
as a treatment approach to NGMGCTs. Transdifferen-
tiating ESC-like NGMGCTs into a benign status may
also be a novel and useful tactic against these fatal
pediatric tumors.
Methods
Patient details and microarray expression data
All procedures were approved by the Institutional
Review Board of the Taipei Veteran General Hospital,
Taiwan and informed consent was obtained from each
subject or the subject’s guardian according to the Hel-
sinki Declaration. In this study, we reviewed a clinical
database containing 176 cases of primary pediatric CNS
GCTs involving patients less than 18 years old; the data-
base was collected from 1970 to 2007 at Taipei Veterans
General Hospital (Taipei VGH). Among them, RNA
samples from the hospital tissue bank were obtained in
13 cases, and mRNA and miRNA microarray analysis
were performed in 13 cases and 12 cases respectively.
The histological types of this series of 176 primary CNS
GCTs and other selected clinical data are summarized
in Additional file 1-A. Excluding operative mortality, the
overall survival rates of the 95 germinoma cases and 59
N G M G C Tc a s e st h a tf o r mt h i ss e r i e sw e r es t u d i e dt o
s u p p o r tt h ed i f f e r e n c ei nm a l i g n a n c ya n do u t c o m e
between these two groups of CNS GCTs. Overall survi-
val was analyzed by the Kaplan-Meier method, and the
log-rank test was applied to compare the cumulative
survival durations in the different patient groups and
this was done using SPSS statistics software (SPSS Inc.,
Chicago, Illinois, USA).
The clinical features of the 22 CNS GCT cases used in
microarray studies are listed in Additional file 1-B in
order to help correlation with the results of the genomic
analysis. In the transcriptome analysis, 13 cases had
both mRNA and miRNA analyzed, except that case 7
had only mRNA analyzed (Additional file 1-B); the latter
was due to insufficient RNA being available. The histo-
logical subtypes in the dataset are germinoma (6), mixed
GCT of germinoma and mature teratoma (1), immature
teratoma (1), mixed GCTs of NGMGCTs category (4),
YST (1). Caucasian embryonic stem cell (ESC) array
data that had been previously published [57], and the
array data of Taiwanese ESC line hES-T3 (T3ES) were
downloaded from the Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo/) database (accession
number GSE9440) [58]. All ESC and GCT mRNA array
data were implemented using the Affymetrix Human
Genome U133 Plus 2.0 chips. The ESC array dataset
was downloaded from GEO datasets GSE7234,
GSE7896, GSE9440 (for Taiwanese ESC lines) together
with GSE9832 and GSE13828. All GCT raw array data
(including gene expression array, microRNA array and
SNP array) are available from the GEO database (acces-
sion number GSE19350).
MicroRNA microarray and data analysis
The Agilent Human miRNA Microarray Kit V2 (Agilent,
Foster City, CA, USA) containing probes for 723 human
microRNAs from the Sanger database v10.1 was used.
GeneSpring GX 9 software (Agilent, USA) was used for
value extraction. A 2-tailed Student’s t-test was then
used for the calculation of the p value for each miRNA
probe. Principal component analysis (PCA) was per-
formed using the Partek Genomics Suite software http://
www.partek.com to provide a visual impression of how
the various sample groups are related. To predict the
downstream mRNA targets of the miRNAs, the TargetS-
can web tool http://genes.mit.edu/targetscan/index.html
was used. The miRNA-target pairs were then mapped
by examining whether there were any candidate miRNA
target genes whose expressions became diminished in a
given group of tumors while there was overexpression
of the correlated miRNAs. A Fisher’se x a c tt e s tw a s
used to examine whether the associations obtained were
by chance or not.
Copy number variation (CNV)
The materials used in the CNV study were fresh frozen
tumor tissues, and the genomic DNA from each sam-
ple was isolated using a DNeasy Blood & Tissue Kit
according to the manufacturer’s instructions (Qiagen,
GmbH, Germany). The Human610-Quad Beadchip
(Illumina Technologies, USA) with 550,000 selected
tag SNPs and 60,000 genetic markers covering 4.7 KB
mean probe spatial resolution was used for the analy-
sis. Normalized bead intensity data obtained for each
sample were loaded into the Illumina BeadStudio™
software version 3.1.3.0, which calculated CNV data
from Intensity and B allele frequency. The calculated
results were then exported to Partek Genomics Suite
software. Chromosome abnormalities were identified
by the cnvPartition algorithm using the default thresh-
old provided by the BeadStudio software and finally
visualized by the Partek Genomics Suite v6.4 http://
www.partek.com/. A copy number baseline dataset
containing 125 Human 1 M HapMap samples (gener-
ated by the Partek Inc.) was used to identify aberrant
chromosomal regions in GCTs.
Gene expression microarray probe preparation and data
analysis
Total RNA collection, cRNA probe preparation, array
hybridization and data analysis were done as described
previously [59]. In brief, fresh tissues were immersed in
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Page 16 of 19Trizol™ solution (Invitrogen Inc., Carlsbad, CA, USA)
and total RNA, including the small RNA fraction, were
extracted and precipitated according to the manufac-
ture’s instructions. RMA log expression units were cal-
culated from Affymetrix™ HG-U133 Plus 2.0 whole
genome array data using the ‘affy’ package included in
the Bioconductor http://www.bioconductor.org suite of
software for the R statistical programming language
http://www.r-project.org. The default RMA settings
were used to background correct, normalize and sum-
marize all expression values. Significant differences
between the sample groups was identified using the
‘limma’ (Linear Models for Microarray Analysis) pack-
age of the Bioconductor suite, and an empirical Bayesian
moderated t-statistic hypothesis test between the two
specified phenotypic groups was performed [60]. To
control for multiple testing errors, we then applied a
false discovery rate algorithm to these p values in order
to calculate a set of q values, thresholds of the expected
proportion of false positives, or false rejections of the
null hypothesis [61].
Heat maps were created by the dChip software http://
www.dchip.org/. Classical multidimensional scaling
(MDS) was performed using the standard function of
the R program to provide a visual impression of how
the various sample groups are related. Gene annotation
was performed by the ArrayFusion web tool http://
microarray.ym.edu.tw/tools/arrayfusion/[62]. Gene
enrichment analysis was performed by the Gene Ontol-
ogy (GO) and KEGG databases using the WebGestalt
http://bioinfo.vanderbilt.edu/webgestalt/[41] and DAVID
Bioinformatics Resources 2008 http://david.abcc.ncifcrf.
gov/[63] interfaces, respectively. The Euclidean distance
between two groups of samples is calculated by the
average linkage measure (the mean of all pair-wise dis-
tances (linkages) between members of the two groups
concerned) [59]. The standard error of the average link-
age distance between two groups (the standard deviation
of pair-wise linkages divided by the square root of the
number of linkages) is quoted when inter-group dis-
tances are compared in the text.
Real-time quantitative polymerase chain reaction
Between 100 ng to 1 μg of total RNA was used to per-
form reverse transcription (RT) using the RevertAid™
Reverse transcriptase kit (Cat. K1622; Fermentas, Glen
Burnie, Maryland, USA) as directed by the manufac-
turer. Real-time PCR reactions were performed using
Maxima™ SYBR Green qPCR Master Mix (Cat. K0222;
Fermentas, Glen Burnie, Maryland, USA), and the speci-
fic products were detected and analyzed using the Ste-
pOne™ sequence detector (Applied Biosystems, USA).
The expression level of each microRNA was normalized
to the expression level of U6 small nuclear RNA, while
the expression level of each gene was normalized to
GAPDH expression. For hsa-miR-142-5p, the forward
primer was 5’-CGCCGGCATAAAGTAGAAAGC-3’ and
the reverse transcription primer was 5’-GTCGTATC-
CAGTGCAGGGTCCGAGGTATTCGCACTGGATAC-
GACAGTAGT-3’. For hsa-miR-335, the forward primer
was 5’-GGCGTCAAGAGCAATAACGAA-3’ and the
reverse transcription primer was 5’-GTCGTATC-
CAGTGCAGGGTCCGAGGTATTCGCACTGGATAC-
GACACATTT-3’. For has-miR-654-3p, the forward
primer was 5’-GCGCTATGTCTGCTGACCAT-3’ and
the reverse transcription primer was 5’-GTCGTATC-
CAGTGCAGGGTCCGAGGTATTCGCACTGGATAC-
GAAAGGTG-3’. For U6, the forward primer was 5’-
CTCGCTTCGGCAGCAC-3’ and the reverse primer
was 5’-AACGCTTCACGAATTTGCG-’3’. For NANOG,
the forward primer was 5’-AGAACTCTCCAA-
CATCCTGAACCT-3’ and the reverse primer was 5’-
TGCCACCTCTTAGATTTCATTCTCT-3’. For SNAI2
(alias SLUG), the forward primer was 5’-TGACAGG-
CATGGAGTAACTCTCA-3’ and the reverse primer
was 5’-AAATGCTGGAGAACTGGAAAG-3’.F o r
POU5F1 (alias OCT4), the forward primer was 5’-
CGGAGGAGTCCCAGGACAT-3’ and the reverse pri-
mer was 5’-CCCACATCGGCCTGTGTATAT. For
GAPDH, the forward primer was 5’-CCAGCCGAGC-
CACATCGCTC-3’ and the reverse primer was 5’-
ATGAGCCCCAGCCTTCTCCAT-3’.
Additional file 1: Summary of patient details and microarray data.
(A) Classification, age distribution, gender ratio, and percentage of
specific types of primary pediatric intracranial germ cell tumors from
Taiwan. (B) Clinical data for the 21 cases of primary pediatric CNS GCTs
used for genomics studies at Taipei VGH. (C) Tumor characteristics
between the extra CNS GCT study (Korkola et al.) and CNS GCT study in
this report.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-
132-S1.PDF]
Additional file 2: Enumeration of differentially expressed probe sets
in germinoma and NGMGCT, respectively. 13 cases were used to
analyze the probe sets specifically enriched in the germinoma group or
NGMGCT group (q < 0.001).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-
132-S2.XLS]
Additional file 3: Distribution of TW NGMGCT genes in the Wnt
signaling pathway. Schematic representation of Wnt signaling pathway
is obtained from KEGG pathway database http://www.genome.jp/kegg/.
The locations of the signature genes are labeled by asterisks.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-
132-S3.PDF]
Additional file 4: Distribution of TW NGMGCT genes in the focal
adhesion pathway. Schematic representation of focal adhesion pathway
is obtained from KEGG pathway database http://www.genome.jp/kegg/.
The locations of the signature genes are labeled by asterisks.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2164-11-
132-S4.PDF]
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Page 17 of 19Additional file 5: Summary of the aberrant chromosome regions in
each tested individuals. 16 cases were used to compare the
chromosome abnormality between different prognosis groups. Detail
data including start point, end point, cytoband, size, and p value were
listed.
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